Caribou Biosciences (CRBU) Net Equity Issued and Repurchased (2021 - 2026)

Caribou Biosciences (CRBU) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $6.3 million, a 62.8% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, down 73.21% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $2.2 million, down from $4.1 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for CRBU reached as high as $11.3 million in Q1 2024 and fell as low as -$115000.0 in Q2 2023.
• Historically, Net Equity Issued and Repurchased has averaged $3.2 million across 4 years, with a median of $2.2 million in 2026.
• Across the five-year window, Net Equity Issued and Repurchased surged 908.82% in 2024 and increased 5.36% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$1000.0 in 2023, then surged by 386400.0% to $3.9 million in 2024, then grew by 5.36% to $4.1 million in 2025, then tumbled by 45.48% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $2.2 million in Q1 2026, $4.1 million in Q4 2025, and $3.9 million in Q4 2024.